Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

April 30, 2013

Conditions
Escherichia Coli Infection
Interventions
BIOLOGICAL

Recombinant fimbrial adhesin dscCfaE

10 ug on study days 0, 21 and 42

BIOLOGICAL

Recombinant fimbrial adhesin dscCfaE

50 ug on study days 0, 21 and 42

BIOLOGICAL

Recombinant fimbrial adhesin dscCfaE

250 ug on study days 0, 21 and 42

BIOLOGICAL

Modified E. coli heat labile enterotoxin LTR192G

50 ug on study days 0, 21 and 42

Trial Locations (1)

20910

Walter Reed Army Institute of Research Clinical Trial Center, Silver Spring

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT01382095 - Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea | Biotech Hunter | Biotech Hunter